Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease

Non-myeloablative allogeneic transplant (NMAT) has a curative potential for patients who are not myeloablative allogeneic transplant (MAT) candidates. We report a phase II trial of a NMAT regimen with cyclophosphamide and fludarabine in 40 patients; 21 of whom had a prior MAT. Day +100 and 1-year tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Paplham, Pamela, Hahn, Theresa, Dubel, Karen, Lipka, Patricia, McCarthy, Philip L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055986/
https://www.ncbi.nlm.nih.gov/pubmed/24936405
http://dx.doi.org/10.1016/j.lrr.2014.03.001
_version_ 1782320761113935872
author Paplham, Pamela
Hahn, Theresa
Dubel, Karen
Lipka, Patricia
McCarthy, Philip L.
author_facet Paplham, Pamela
Hahn, Theresa
Dubel, Karen
Lipka, Patricia
McCarthy, Philip L.
author_sort Paplham, Pamela
collection PubMed
description Non-myeloablative allogeneic transplant (NMAT) has a curative potential for patients who are not myeloablative allogeneic transplant (MAT) candidates. We report a phase II trial of a NMAT regimen with cyclophosphamide and fludarabine in 40 patients; 21 of whom had a prior MAT. Day +100 and 1-year transplant-related mortality (TRM) post-NMAT were 13% and 34%, respectively. Day +100 and 1-year Overall/Progression-Free Survival (OS/PFS) were 80%/65% and 43%/25%, respectively. OS was higher in patients with KPS≥90 and lower in recipient/donor CMV+/− vs. other combinations. FluCy has low TRM and is curative in about 20% of high-risk patients.
format Online
Article
Text
id pubmed-4055986
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-40559862014-06-16 Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease Paplham, Pamela Hahn, Theresa Dubel, Karen Lipka, Patricia McCarthy, Philip L. Leuk Res Rep Article Non-myeloablative allogeneic transplant (NMAT) has a curative potential for patients who are not myeloablative allogeneic transplant (MAT) candidates. We report a phase II trial of a NMAT regimen with cyclophosphamide and fludarabine in 40 patients; 21 of whom had a prior MAT. Day +100 and 1-year transplant-related mortality (TRM) post-NMAT were 13% and 34%, respectively. Day +100 and 1-year Overall/Progression-Free Survival (OS/PFS) were 80%/65% and 43%/25%, respectively. OS was higher in patients with KPS≥90 and lower in recipient/donor CMV+/− vs. other combinations. FluCy has low TRM and is curative in about 20% of high-risk patients. Elsevier 2014-04-18 /pmc/articles/PMC4055986/ /pubmed/24936405 http://dx.doi.org/10.1016/j.lrr.2014.03.001 Text en © 2014 The Authors http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
spellingShingle Article
Paplham, Pamela
Hahn, Theresa
Dubel, Karen
Lipka, Patricia
McCarthy, Philip L.
Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease
title Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease
title_full Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease
title_fullStr Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease
title_full_unstemmed Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease
title_short Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease
title_sort fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055986/
https://www.ncbi.nlm.nih.gov/pubmed/24936405
http://dx.doi.org/10.1016/j.lrr.2014.03.001
work_keys_str_mv AT paplhampamela fludarabineandcyclophosphamideprovidesanonmyeloablativealternativeconditioningregimenwithlowtransplantrelatedmortalityandcontrolofhighriskdisease
AT hahntheresa fludarabineandcyclophosphamideprovidesanonmyeloablativealternativeconditioningregimenwithlowtransplantrelatedmortalityandcontrolofhighriskdisease
AT dubelkaren fludarabineandcyclophosphamideprovidesanonmyeloablativealternativeconditioningregimenwithlowtransplantrelatedmortalityandcontrolofhighriskdisease
AT lipkapatricia fludarabineandcyclophosphamideprovidesanonmyeloablativealternativeconditioningregimenwithlowtransplantrelatedmortalityandcontrolofhighriskdisease
AT mccarthyphilipl fludarabineandcyclophosphamideprovidesanonmyeloablativealternativeconditioningregimenwithlowtransplantrelatedmortalityandcontrolofhighriskdisease

Ejemplares similares